Connect your AI

Pacira BioSciences, Inc. PCRX Income Tax

Income Tax at other companies

Avanos MedicalAVNS

$2.5M-19.4%

Collegium Pharmaceutical, Inc.COLL

$4.24M+502%

Segments

By segment

Reportable Segment$2.08M-46.5%

Other financials

Income statement

Revenue$177.4M+5.0%

Gross profit$141.0M+4.7%

Operating income$6.9M+247%

Net income$2.9M-39.4%

EPS (diluted)$0.07-30.0%

Balance sheet

Cash & equivalents$144.3M-49.1%

Total debt$411.2M+15.3%

Total equity$653.9M-18.1%

Total assets$1.2B-23.8%

Cash flow

Operating cash flow$25.7M-27.6%

CapEx$2.7M-68.1%

Free cash flow$23.0M-14.7%

Valuation

Market cap$942.78M-14.5%

Enterprise value$1.21B+2.6%

P/E183.5×—

P/S1.3×-0.3×

Profitability

Gross margin79.3%+1.7pp

Operating margin3.3%—

Net margin0.7%—

FCF margin18.1%-4.6pp

Returns & leverage

Return on equity0.7%—

Debt / equity0.6×+0.2×

Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Pacira BioSciences, Inc.'s income tax?: Pacira BioSciences, Inc. (PCRX) reported income tax of $2.08M in Q1 2026.
How has Pacira BioSciences, Inc.'s income tax changed year-over-year?: Pacira BioSciences, Inc.'s income tax decreased by 46.5% year-over-year, from $3.89M to $2.08M.
What is the long-term trend for Pacira BioSciences, Inc.'s income tax?: Over 3 years (2021 to 2024), Pacira BioSciences, Inc.'s income tax has grown at a 33.0% compound annual growth rate (CAGR), from $15.49M to $36.45M.
What does income tax mean?: Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.